Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H21O10P |
Molecular Weight | 452.3485 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=CC(OC)=C1OC)C(=O)C2=C(C)OC3=C2C=CC(OC)=C3OP(O)(O)=O
InChI
InChIKey=MYDHDVLPMRNDAZ-UHFFFAOYSA-N
InChI=1S/C20H21O10P/c1-10-16(17(21)11-8-14(26-3)19(28-5)15(9-11)27-4)12-6-7-13(25-2)20(18(12)29-10)30-31(22,23)24/h6-9H,1-5H3,(H2,22,23,24)
BNC105P, a vascular disrupting agent, is a disodium phosphate ester prodrug of BNC105. BNC105P is a tubulin polymerization inhibitor that suppresses cancer cell proliferation. BNC105P participated in phase I/II trial for patients with metastatic renal cell carcinoma. Although the primary endpoint was not met in an unselected population, correlative studies suggested several biomarkers that warrant further prospective evaluation. Besides, BNC105P was involved in phase II clinical trial as second-line chemotherapy for advanced malignant pleural mesothelioma. The drug was safe and tolerable, but the sole response was insufficient to warrant further research as a single agent. In addition, BNC105P in combination with Ibrutinib was studied in phase I trials for patients with chronic lymphocytic leukemia to determine the preliminary assessment of the efficacy.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. | 2011 Aug 1 |
|
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. | 2013 Sep |
|
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. | 2015 Aug 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25788492
Metastatic Renal Cell Carcinoma: In the phase I study (N = 15), a dose of BNC105P at 16 mg/m(2) with everolimus at 10 mg daily was identified as the recommended phase II dose.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TO9V2XZF53
Created by
admin on Fri Dec 15 19:46:58 GMT 2023 , Edited by admin on Fri Dec 15 19:46:58 GMT 2023
|
PRIMARY | |||
|
DB06313
Created by
admin on Fri Dec 15 19:46:58 GMT 2023 , Edited by admin on Fri Dec 15 19:46:58 GMT 2023
|
PRIMARY | |||
|
945772-45-2
Created by
admin on Fri Dec 15 19:46:58 GMT 2023 , Edited by admin on Fri Dec 15 19:46:58 GMT 2023
|
PRIMARY | |||
|
DTXSID00241537
Created by
admin on Fri Dec 15 19:46:58 GMT 2023 , Edited by admin on Fri Dec 15 19:46:58 GMT 2023
|
PRIMARY | |||
|
16678087
Created by
admin on Fri Dec 15 19:46:58 GMT 2023 , Edited by admin on Fri Dec 15 19:46:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)